Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3451-3460 Newer>

Managed Care January 2007	Change From Salary to Relative Value Units Leads to Higher Income for Physicians A Minnesota medical group that contracted with HealthPartners was able to improve cost of care, physician compensation, and patient access without harming patient satisfaction when the group converted from a salary payment system for physicians to one solely dependent on physician productivity.
Managed Care January 2007	New Coagulant Bypasses Clotting Dysfunction in Hemophilia The less common form of hemophilia - acquired hemophilia - can now be treated with recombinant activated factor VII.
BusinessWeek February 12, 2007 Bruce Einhorn	Stem-Cell Refugees Americans are flocking to China for therapy.
Chemistry World February 2, 2007 Victoria Gill	AstraZeneca Follows Pfizer in Slashing Workforce The Anglo-Swedish pharmaceutical hopes that by streamlining its operation it can offset the growing financial threat from cheap generic copies of its best-selling blood pressure drug. Nevertheless, the company has reported unexpectedly cheerful fourth quarter profits.
The Motley Fool January 31, 2007 Brian Lawler	Mylan on the Generic Attack Two new drug approvals for the generic drugmaker come in the midst of a changing regulatory environment. Investors, take note.
The Motley Fool January 31, 2007 Brian Lawler	FDA Says Hurray for More Drug Safety The FDA outlines its proposal to increase drug safety. Whatever the FDA does, pharmaceutical investors should hope that its renewed interest in drug safety doesn't make the already lengthy process of bringing drugs to market any longer.
The Motley Fool January 31, 2007 Brian Lawler	You're Only Hurting Yourself, Thailand Thailand's decision to allow generics could do more harm than good. Investors, take note.
The Motley Fool January 31, 2007 Brian Gorman	Merck's Special Interest Merck is likely to succeed in getting states to mandate HPV vaccination. Still, investors shouldn't necessarily bet everything on Gardasil.
The Motley Fool January 31, 2007 Brian Lawler	No Snoozing for Sepracor The pharmaceutical sees troubling sales trends with a key product. Investors, take note.
The Motley Fool January 31, 2007 Brian Lawler	Merck Plays the Waiting Game New acquisitions may help the drugmaker weather tough times. Investors, take note.
<Older 3451-3460 Newer> Return to current articles.